Related Experiment Video
Updated: Mar 20, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Pranshu Bansal1, Diaa Osman1, Gregory N Gan2
1Department of Internal Medicine, Division of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque, NM, USA; Hematology/Oncology Fellowship Program, University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Abstract:
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.
Insights
Novel targeted therapies are expanding treatment options for lung adenocarcinoma, a common non-small cell lung cancer (NSCLC). Advances in molecular testing enable personalized treatment strategies against specific oncogenic targets in NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung adenocarcinoma is the most prevalent form of non-small cell lung cancer (NSCLC).
- Significant advancements in understanding oncogenic drivers like EGFR mutations and ALK rearrangements have revolutionized treatment approaches.
- Targeted therapies have demonstrated efficacy, improving outcomes for patients with specific molecular profiles.
Purpose of the Study:
- To review emerging targeted therapies for non-squamous NSCLC.
- To highlight novel agents targeting key oncogenic drivers.
- To discuss the impact of molecular testing on personalized medicine in NSCLC.
Main Methods:
- Literature review of recent clinical trials and research publications.
- Analysis of targeted therapies directed against specific molecular alterations.
- Synthesis of data on efficacy and patient selection for novel agents.
Main Results:
- Identification of multiple novel targeted therapies for NSCLC.
- Focus on agents targeting EGFR, ALK, ROS1, BRAF, MET, HER2, VEGFR2, RET, and NTRK.
- Demonstration of improved outcomes with personalized therapeutic strategies.
Conclusions:
- The landscape of NSCLC treatment is rapidly evolving with new targeted therapies.
- Personalized medicine, guided by molecular testing, is becoming standard in non-squamous NSCLC care.
- Continued research and development are crucial for further optimizing lung cancer treatment.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies